Ensoma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ensoma sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Ensoma: 6 sponsored US clinical trials, 2 recruiting.
Ensoma sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is X-Linked Chronic Granulomatous Disease, with 1 trials.
Upper-quartile sponsor footprint
Ensoma sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
NCT06876363
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
NCT05445128
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
NCT04762875
Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
NCT04154670
Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor
NCT03932864
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Ensoma pipeline
2 recruiting of 6 indexed (33% open); 2 completed (33%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: X-Linked Chronic Granulomatous Disease (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ensoma: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Ensoma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Ensoma page
6 registered trials is a research-attention snapshot, not an endorsement of Ensoma or any single study.
- 2 of Ensoma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- X-Linked Chronic Granulomatous Disease is the condition Ensoma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See X-Linked Chronic Granulomatous Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ensoma pipeline card: 6 registered trials from official public datasets.Report a data error.